Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

EVGNBearishLegalnews

High materiality7/10

Evogene Faces Nasdaq Bid-Price Issue, Receives 180-Day Extension

Sep 30, 2026, 7:31 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A breach of Nasdaq's minimum bid price creates immediate delisting risk; even with extensions, a protracted below-$1 price could compress liquidity and valuation; historical cases show pop only after corrective actions or support from buybacks/reverse splits.

AI summary

What happened, with direct paths to the underlying reporting

Evogene disclosed Nasdaq notified it of non-compliance with the $1 minimum bid rule after closing prices remained below $1. The company has 180 days (through Sept 28, 2026) and a further extension to March 29, 2027 to restore the price by maintaining $1 for 10 consecutive trading days. A reverse split could be considered; Tel Aviv listing remains unaffected.

Nasdaq cited EVGN's closing bid below $1; non-compliance notice issued.
Initial 180-day cure period through Sept 28, 2026.
Eligible for additional 180 days to March 29, 2027 to regain compliance.
Regain by $1 closing price for 10 consecutive trading days.
Potential reverse split; Tel Aviv listing unaffected; trading continues on Nasdaq.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.